-
-
CINCINNATI, Sept. 26 /PRNewswire-USNewswire/ -- Identification of a molecular communications pathway that influences the mobilization of hematopoietic (blood) stem cells could lead to targeted therapies for improving bone marrow transplant success rates.
In a bed-side to bench approach, researchers at Cincinnati Children's Hospital Medical Center report Sept. 26 in Nature Medicine that pharmacological inhibition of a signaling pathway triggered by Egfr (epidermal growth factor receptor) increased the mobilization of hematopoietic stem cells in mice. The finding provides a scientific basis for enhancing the effectiveness of autologous bone marrow transplants, in which the recipient donates his or her own stem cells prior to the procedure.
-
HAIFA, Israel -- Pluristem Life Systems, Inc. (OTC BB:PLRS), a biotechnology company dedicated to the commercialization of cell therapy products, toda...
-
MENLO PARK, Calif. -- Geron Corporation (Nasdaq:GERN) announced today the publication of studies demonstrating that hematopoietic stem cells (HSCs) de...
-
... relief to allow harvesting of "hematopoietic stem cells." The complaint is not crystal clear on...
-
Business Editors/Health/Medical Writers
MENLO PARK, Calif.--(BUSINESS WIRE)--May 22, 2003
Geron Corporation (Nasdaq:GERN) announced today publicat...
-
The processed blood contains hematopoietic or blood-forming stem cells, which have been used in transplants instead of bone marrow to treat leukemia and other diseases of the blood and immune system. The law also requires the state Department of Health to conduct a public awareness campaign about cord blood banking and maintain quality ratings on blood banks. The results of about 500 stem cell transplants in children with genetic and hematologic disorders indicated that the one-year survival rate may be as high as 73 percent for sibling blood matches but only 29 percent for unrelated donors, according to the APA.
-
Business Editors/Health and Medical Writers
MENLO PARK, Calif.--(BUSINESS WIRE)--Jan. 21, 2003
Geron Also Licenses Methods To Prevent Immune Rejec...
-
Mark Kiel at the University of Michigan and colleagues compared gene expression profiles from hematopoietic stem cells (HSCs) and more differentiated progeny, the multipotent hematopoietic progenitors.
-
WASHINGTON, Oct. 7 /PRNewswire-USNewswire/ -- The American Society of Hematology (ASH) will honor Harvey F. Lodish, PhD, and Mary M. Horowitz, MD, MS, with the ASH Mentor Award in recognition of the significant impact they have made in the training and career development of many physicians and scientists in the field of hematology. The prominent hematologists will receive their awards during the 52nd ASH Annual Meeting in Orlando, Florida.
Dr. Lodish, the Mentor Award winner for Basic Science, is a founding member of the Whitehead Institute for Biomedical Research and professor of biology and professor of bioengineering at the Massachusetts Institute of Technology (MIT). A leader in the field of membrane biology, Dr. Lodish isolated key genes involved in formation and function of red bl...
...She is an expert on the subject of hematopoietic stem cell transplantation, specifically focusing h...